FDA Issues Warning Letter to Medline Over Significant cGMP Violations, Including Microbial Contamination Failures
Key Insights
On June 2, 2026, the FDA published a warning letter to Medline (NASDAQ: MDLN) citing significant violations of Current Good Manufacturing Practice (cGMP) regulations for finished pharmaceuticals.
The FDA found Medline failed to thoroughly investigate microbial contamination incidents in finished drug products and cited inadequate cleaning practices.
This marks the second FDA warning letter issued to Medline in two months, according to a Reuters report.
The U.S. Food and Drug Administration has issued a warning letter to Medline Inc. (search) (NASDAQ: MDLN) detailing significant violations of Current Good Manufacturing Practice (cGMP) regulations for finished pharmaceuticals. The warning letter, dated May 28, 2026, was published by the FDA on June 2, 2026, and has triggered both a notable stock decline and a securities law investigation by the law firm Kaplan Fox & Kilsheimer LLP (search).
The FDA's warning letter states that Medline "failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications." According to a June 3, 2026 Reuters article cited in the Kaplan Fox announcement, the FDA further determined that "the Company failed to thoroughly investigate microbial contamination incidents in finished drug products and also cited inadequate cleaning practices."
This latest enforcement action represents the second FDA warning letter directed at Medline within a two-month period, as reported by Reuters. The repeated nature of the manufacturing quality citations raises concerns about the company's quality management systems and its ability to maintain compliance with federal pharmaceutical manufacturing standards.
Following the publication of the FDA warning letter, Medline's stock price fell $2.56 per share, representing a decline of 7.16%, to close at $33.19 per share on June 2, 2026.
In response to these developments, Kaplan Fox & Kilsheimer LLP (search), a national law firm specializing in securities litigation, has announced an investigation into potential securities law violations by Medline. The firm is encouraging Medline investors who have suffered losses, as well as individuals with information relevant to the investigation, to come forward.
Kaplan Fox, which maintains offices in New York, Oakland, Los Angeles, Chicago, and New Jersey, brings over 50 years of experience in securities litigation to the investigation. The firm has indicated that the investigation will examine whether Medline may have violated federal securities laws in connection with the manufacturing quality issues identified by the FDA.